Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Convalescent plasma-Erasmus Medical Center-COVID-19 refers to a passive immunotherapy developed and studied by Erasmus Medical Center for the treatment of COVID-19. The therapy consists of plasma containing high titers (at least 1:80) of anti-SARS-CoV-2 neutralizing antibodies collected from donors who have recovered from the virus. By providing these pre-formed antibodies to hospitalized or early-stage patients, the treatment aims to neutralize viral particles, reduce viral load, and prevent the progression of the disease. This specific institutional program was evaluated in the ConCOVID randomized trial (NCT04342182), which compared the infusion of 300mL of convalescent plasma against standard of care in symptomatic COVID-19 patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on convalescent plasma-Erasmus Medical Center-COVID-19.